Tag: SkylineDx
-
New SkylineDx Data Show Merlin CP-GEP Test Improves Melanoma Risk Stratification
Introduction: A new benchmark in melanoma risk assessment Recent analyses from SkylineDx present compelling evidence that the Merlin CP-GEP Test offers superior metastatic-risk stratification for melanoma compared with benchmarks released by a major competitor. In a field where precise risk categorization directly informs surgical decisions and patient outcomes, these findings could influence standard-of-care considerations for…
-
Merlin CP-GEP Test from SkylineDx Outperforms Competitors in Melanoma Risk Stratification
New Evidence Places Merlin CP-GEP Test at the Forefront of Melanoma Risk Stratification In the fast-evolving field of melanoma care, precision risk assessment is critical for guiding surgical and medical decisions. SkylineDx has released new data indicating that its Merlin CP-GEP Test provides superior metastatic-risk stratification for melanoma patients, along with more accurate predictions of…
-
SkylineDx Data Underscores Merlin CP-GEP Test’s Superior Melanoma Risk Stratification
New Findings Highlight Merlin CP-GEP Test Performance Fresh data from SkylineDx indicate that the Merlin CP-GEP test offers superior metastatic-risk stratification for melanoma and more accurate prediction of sentinel lymph node biopsy (SLNB) outcomes than rival benchmarks. In a landscape where accurate risk stratification informs crucial treatment decisions, these results position Merlin CP-GEP as a…